SpFN SARS-CoV Vaccine Description
SpFN was developed internally at Walter Reed Army Institute of Research (WRAIR).
The vaccine, currently called “SpFN” (short for “spike ferritin nanoparticle”) employs ferritin, a protein found in almost all living organisms.
By attaching a certain type of spike protein to a polymerized version of ferritin, WRAIR scientists hope the resulting vaccination dose will block COVID-19 infection.
SpFN SARS-CoV Vaccine Indication
SpFN SARS-CoV-2 vaccine is indicated to prevent COVID-19 disease caused by the SARS-C0V-2 vaccine.
SpFN SARS-CoV Vaccine Clinical Trials
SpFN expects to begin Phase 1 clinical trials later this year. The news was delivered during a press briefing with national media outlets on October 14.
SpFN SARS-CoV Vaccine News
October 16, 2020 - WRAIR Announces COVID-19 Vaccine Candidate, Targets Clinical Trial Date